Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study

Int J Antimicrob Agents. 2017 Jul;50(1):68-73. doi: 10.1016/j.ijantimicag.2017.02.020. Epub 2017 May 10.

Abstract

Optimal dosing of β-lactam antibiotics in critically ill patients is a challenge given the unpredictable pharmacokinetic profile of this patient population. Several studies have shown intermittent dosing to often yield inadequate drug concentrations. Continuous dosing is an attractive alternative from a pharmacodynamic point of view. This study evaluated whether, during continuous dosing, piperacillin concentrations reached and maintained a pre-defined target in critically ill patients. Adult patients treated with piperacillin by continuous dosing in the intensive care unit of a university medical centre in The Netherlands were prospectively studied. Total and unbound piperacillin concentrations drawn at fixed time points throughout the entire treatment course were determined by liquid chromatography-tandem mass spectrometry. A pharmacokinetic combined target of a piperacillin concentration ≥80 mg/L, reached within 1 h of starting study treatment and maintained throughout the treatment course, was set. Eighteen patients were analysed. The median duration of monitored piperacillin treatment was 60 h (interquartile range, 33-96 h). Of the 18 patients, 5 (27.8%) reached the combined target; 15 (83.3%) reached and maintained a less strict target of >16 mg/L. In this patient cohort, this dosing schedule was insufficient to reach the pre-defined target. Depending on which target is to be met, a larger initial cumulative dose is desirable, combined with therapeutic drug monitoring.

Keywords: Continuous dosing; Critical care; Piperacillin; β-Lactam.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacokinetics*
  • Chromatography, Liquid
  • Critical Illness*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Netherlands
  • Penicillanic Acid / administration & dosage
  • Penicillanic Acid / analogs & derivatives*
  • Penicillanic Acid / pharmacokinetics
  • Piperacillin / administration & dosage
  • Piperacillin / pharmacokinetics
  • Piperacillin, Tazobactam Drug Combination
  • Plasma / chemistry
  • Prospective Studies
  • Tandem Mass Spectrometry
  • Young Adult
  • beta-Lactamase Inhibitors / administration & dosage*
  • beta-Lactamase Inhibitors / pharmacokinetics*

Substances

  • Anti-Bacterial Agents
  • beta-Lactamase Inhibitors
  • Piperacillin, Tazobactam Drug Combination
  • Penicillanic Acid
  • Piperacillin